Research ExplorerPublicationsDirect percutaneous transaxillary implantation of a novel se...

Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis

Standard

Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis. / Deuschl, Florian; Schofer, Niklas; Seiffert, Moritz; Hakmi, Samer; Mizote, Isamu; Schaefer, Andreas; Schirmer, Johannes; Reichenspurner, Hermann; Blankenberg, Stefan; Conradi, Lenard; Schäfer, Ulrich.

In: CATHETER CARDIO INTE, Vol. 90, No. 7, 01.12.2017, p. 1167-1174.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Deuschl, F, Schofer, N, Seiffert, M, Hakmi, S, Mizote, I, Schaefer, A, Schirmer, J, Reichenspurner, H, Blankenberg, S, Conradi, L & Schäfer, U 2017, 'Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis', CATHETER CARDIO INTE, vol. 90, no. 7, pp. 1167-1174. https://doi.org/10.1002/ccd.26986

APA

Deuschl, F., Schofer, N., Seiffert, M., Hakmi, S., Mizote, I., Schaefer, A., Schirmer, J., Reichenspurner, H., Blankenberg, S., Conradi, L., & Schäfer, U. (2017). Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis. CATHETER CARDIO INTE, 90(7), 1167-1174. https://doi.org/10.1002/ccd.26986

Vancouver

Deuschl F, Schofer N, Seiffert M, Hakmi S, Mizote I, Schaefer A et al. Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis. CATHETER CARDIO INTE. 2017 Dec 1;90(7):1167-1174. https://doi.org/10.1002/ccd.26986

Bibtex

@article{6fff2dd4296a46e98a292209d3c83bfa,
title = "Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis",
abstract = "OBJECTIVES: The aim of this study was to evaluate safety, feasibility, and efficacy of transaxillary TAVI using a novel self-expandable transcatheter heart valve (THV) via a direct percutaneous technique.METHODS: The analysis comprises 12 consecutive patients with severe aortic stenosis treated with the ACURATE Neo{\texttrademark} THV (Symetis) by direct percutaneous transaxillary access.RESULTS: Patients presented with a mean age of 79.9 ± 6.2 years and high calculated surgical risk (logEuroSCORE I: 19.55 ± 15.00%; STS PROM score: 5.42 ± 3.25%). Transaxillary TAVI was performed in 11/12 via the left and in 1/12 via the right-sided axillary artery. Device success was achieved in all patients (12/12). Mortality rate at 30 days was 0% (0/12). No major and one minor access site complication (1/12) occurred. No major or life-threatening access site-related bleeding resulted. None of the patients suffered from postprocedural stroke/transient ischemic attack. There was no need for a permanent pacemaker. Mean effective orifice area post implantation was 2.1 ± 0.29 cm2 and mean aortic gradient 6.2 ± 1.5 mm Hg. In none of the patients, greater than moderate aortic regurgitation or paravalvular leakage was detected at discharge (0/12).CONCLUSIONS: Our study suggests that the implantation of the second-generation self-expandable ACURATE Neo{\texttrademark} via a transaxillary access is technically feasible and safe and yields excellent short-term clinical results. {\textcopyright} 2017 Wiley Periodicals, Inc.",
keywords = "Aged, Aged, 80 and over, Aortic Valve Insufficiency/etiology, Aortic Valve Stenosis/diagnostic imaging, Axillary Artery/diagnostic imaging, Catheterization, Peripheral/adverse effects, Computed Tomography Angiography, Coronary Angiography/methods, Databases, Factual, Echocardiography, Transesophageal, Feasibility Studies, Female, Heart Valve Prosthesis, Humans, Male, Multidetector Computed Tomography, Prosthesis Design, Prosthesis Failure, Punctures, Retrospective Studies, Severity of Illness Index, Time Factors, Transcatheter Aortic Valve Replacement/adverse effects, Treatment Outcome",
author = "Florian Deuschl and Niklas Schofer and Moritz Seiffert and Samer Hakmi and Isamu Mizote and Andreas Schaefer and Johannes Schirmer and Hermann Reichenspurner and Stefan Blankenberg and Lenard Conradi and Ulrich Sch{\"a}fer",
note = "{\textcopyright} 2017 Wiley Periodicals, Inc.",
year = "2017",
month = dec,
day = "1",
doi = "10.1002/ccd.26986",
language = "English",
volume = "90",
pages = "1167--1174",
journal = "CATHETER CARDIO INTE",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis

AU - Deuschl, Florian

AU - Schofer, Niklas

AU - Seiffert, Moritz

AU - Hakmi, Samer

AU - Mizote, Isamu

AU - Schaefer, Andreas

AU - Schirmer, Johannes

AU - Reichenspurner, Hermann

AU - Blankenberg, Stefan

AU - Conradi, Lenard

AU - Schäfer, Ulrich

N1 - © 2017 Wiley Periodicals, Inc.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - OBJECTIVES: The aim of this study was to evaluate safety, feasibility, and efficacy of transaxillary TAVI using a novel self-expandable transcatheter heart valve (THV) via a direct percutaneous technique.METHODS: The analysis comprises 12 consecutive patients with severe aortic stenosis treated with the ACURATE Neo™ THV (Symetis) by direct percutaneous transaxillary access.RESULTS: Patients presented with a mean age of 79.9 ± 6.2 years and high calculated surgical risk (logEuroSCORE I: 19.55 ± 15.00%; STS PROM score: 5.42 ± 3.25%). Transaxillary TAVI was performed in 11/12 via the left and in 1/12 via the right-sided axillary artery. Device success was achieved in all patients (12/12). Mortality rate at 30 days was 0% (0/12). No major and one minor access site complication (1/12) occurred. No major or life-threatening access site-related bleeding resulted. None of the patients suffered from postprocedural stroke/transient ischemic attack. There was no need for a permanent pacemaker. Mean effective orifice area post implantation was 2.1 ± 0.29 cm2 and mean aortic gradient 6.2 ± 1.5 mm Hg. In none of the patients, greater than moderate aortic regurgitation or paravalvular leakage was detected at discharge (0/12).CONCLUSIONS: Our study suggests that the implantation of the second-generation self-expandable ACURATE Neo™ via a transaxillary access is technically feasible and safe and yields excellent short-term clinical results. © 2017 Wiley Periodicals, Inc.

AB - OBJECTIVES: The aim of this study was to evaluate safety, feasibility, and efficacy of transaxillary TAVI using a novel self-expandable transcatheter heart valve (THV) via a direct percutaneous technique.METHODS: The analysis comprises 12 consecutive patients with severe aortic stenosis treated with the ACURATE Neo™ THV (Symetis) by direct percutaneous transaxillary access.RESULTS: Patients presented with a mean age of 79.9 ± 6.2 years and high calculated surgical risk (logEuroSCORE I: 19.55 ± 15.00%; STS PROM score: 5.42 ± 3.25%). Transaxillary TAVI was performed in 11/12 via the left and in 1/12 via the right-sided axillary artery. Device success was achieved in all patients (12/12). Mortality rate at 30 days was 0% (0/12). No major and one minor access site complication (1/12) occurred. No major or life-threatening access site-related bleeding resulted. None of the patients suffered from postprocedural stroke/transient ischemic attack. There was no need for a permanent pacemaker. Mean effective orifice area post implantation was 2.1 ± 0.29 cm2 and mean aortic gradient 6.2 ± 1.5 mm Hg. In none of the patients, greater than moderate aortic regurgitation or paravalvular leakage was detected at discharge (0/12).CONCLUSIONS: Our study suggests that the implantation of the second-generation self-expandable ACURATE Neo™ via a transaxillary access is technically feasible and safe and yields excellent short-term clinical results. © 2017 Wiley Periodicals, Inc.

KW - Aged

KW - Aged, 80 and over

KW - Aortic Valve Insufficiency/etiology

KW - Aortic Valve Stenosis/diagnostic imaging

KW - Axillary Artery/diagnostic imaging

KW - Catheterization, Peripheral/adverse effects

KW - Computed Tomography Angiography

KW - Coronary Angiography/methods

KW - Databases, Factual

KW - Echocardiography, Transesophageal

KW - Feasibility Studies

KW - Female

KW - Heart Valve Prosthesis

KW - Humans

KW - Male

KW - Multidetector Computed Tomography

KW - Prosthesis Design

KW - Prosthesis Failure

KW - Punctures

KW - Retrospective Studies

KW - Severity of Illness Index

KW - Time Factors

KW - Transcatheter Aortic Valve Replacement/adverse effects

KW - Treatment Outcome

U2 - 10.1002/ccd.26986

DO - 10.1002/ccd.26986

M3 - SCORING: Journal article

C2 - 28296065

VL - 90

SP - 1167

EP - 1174

JO - CATHETER CARDIO INTE

JF - CATHETER CARDIO INTE

SN - 1522-1946

IS - 7

ER -